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September 2010804 AbstractsAnatomic Patterns of Failure After Infrainguinal Percutaneous Revas-
cularization
Mounir J. Haurani, MD, Mark F. Conrad, MD, Vikram Paruchuri, and
Richard P. Cambria, MD, Massachusetts General Hospital, Boston, Mass
Objective: Percutaneous revascularization (PTA) of infrainguinal oc-
clusive disease is associated with a significant recurrence rate, with a 15% to
25% reintervention rate to maintain secondary patency. Other studies have
focused on clinical predictors of such failure, but little is known of the
anatomy of such failures, which is the goal of this study.
Methods: Of 1100 limbs that underwent infrainguinal PTA from
2002-2007, 40% failed based on worsening ABIs, clinical symptoms, ampu-
tation, or reintervention. A total of 150 limbs underwent femoral-popliteal
PTA and had follow-up arteriograms for evaluation. Lesions were stratified
into proximal, middle (adductor canal), and distal (popliteal). Angiographic
findings from the initial PTA were compared with the follow-up study.
Results: Of the 150 limbs in the cohorts, 38% underwent initial PTA
for critical limb ischemia, with 10% limb loss. The mean length of time to
recurrence was 13.2 months, with 70% of patients recurring by that time
point. The distribution of disease was not different between the initial PTA
and the follow-up angiography (70% vs 64% [P .2] proximal, 79% vs 78%
[P  .1] middle, and 28% vs 30% [P  .8] distal femoral-popliteal). There
was no change in multilevel disease from initial PTA either (64% vs 58% P
.3). Significantly more middle femoral-popliteal segments were initially
occluded (25% proximal, 33%middle, and 12% distal; P .001). An initially
occluded segment did not increase the likelihood of new or worsening
disease on repeat angiography. Tibial runoff deteriorated in 11% of patients
but did not correlate with amputation, initial lesion location, or severity.
Initially, 40% of the limbs treated underwent stenting in at least one
segment; this did not predict worsening disease. In 68% of the limbs treated,
the site of recurrence was the same as the initial PTA site, and in 16%, the
disease was immediately adjacent to the initial PTA site.
Conclusions: Recurrent lesions after infrainguinal PTA tend to occur
within the first year and most occur at or immediately adjacent to the site of
initial treatment. There was no difference in the location of the recurrent
disease when compared with primary PTA site. Presence of an occlusion was
not predictive of worsening disease within the femoral-popliteal artery or the
location of the recurrence.
Scientific Session II
Role of IVUS Versus Venograms in Assessment of Iliac-Femoral Vein
Stenosis
Anil Hingorani,MD, Saadi Alhabouni, MD, Enrico Ascher, MD, Natalie
Marks, MD RVT, Alexsander Shiferson, DO, Kapil Gopal, MD, Daniel
Jung, DO, and Theresa Jacob, PhD,MaimononidesMedical Center, Brook-
lyn, NY
Objective: Lower extremity venous stasis disease could be related to
outflow obstruction in the iliac-femoral vein segments due to stenosis or
extrinsic compression. Conventional methods to assess these vein segments
include transcutaneous ultrasonography and ascending venography. The
transcutaneous approach has a low sensitivity, and venography can miss
significant lesions as the assessment is undertaken in a single view. We
assessed the role of intravenous ultrasound (IVUS) imaging in detecting the
location as well as the degree of stenosis in the iliac-femoral vein segments.
Methods: IVUS and ascending venography were used to evaluate
outflow obstruction/stenosis in 104 patients with chronic lower extremity
venous stasis disease. The location and degree of any stenosis were noted. A
significant stenosis was defined as a 50% reduction in the diameter of the vein
relative to the adjacent vein segments. Patients with significant stenosisunderwent venous stenting to restore outflow. The results of venography
and IVUS were compared.
Results: Forty-six (44.2%) patients had no evidence of stenosis on
venography or IVUS and hence received no stents, but 58 (55.8%) had
significant stenotic lesions on IVUS. Among those, 10 (17.2%) had no
detectable lesion on venogram and would have been missed. In 24 patients
(41.4%), venography failed to identify all stenotic lesions or resulted in
inaccurate localization of the lesion. Only 24 patients (41.4%) had stenotic
lesions on venogram that conformed anatomically to the lesions detected on
IVUS.
Conclusions: In assessing patients with lower extremity venous stasis
disease for iliac-femoral vein stenosis/obstruction, venography alone can
result in poor localization (50% specificity) and can even miss significant
stenotic lesions (82.8% sensitivity). IVUS is a more sensitive and accurate
method and should be included in all such evaluations.
Venous Ablation Can Be Performed Safely on High-Risk Patients
Kathleen J. Ozsvath, MD, Stephanie Saltzberg, MD, John B. Taggert, MD,
Benjamin B. Chang, MD, Paul B. Kreienberg, MD, Manish Mehta, MD,
MPH, Philip S. K. Paty, MD, Sean P. Roddy, MD, Yaron Sternbach, MD,
and R. Clement Darling III, MD, Albany Medical College, Albany, NY
Introduction: Patients with a previous history of deep vein thrombosis
(DVT) or a family history of DVT are considered at high risk for thrombotic
complications (DVT) after endovenous ablation (EVA). In this study, we
examine our outcomes on patients presenting for “high-risk” EVA.
Methods:We reviewed our vascular registry for all patients undergoing
EVA from 2006-2008. All patients were evaluated with venous ultrasonog-
raphy and initially treated with a minimum of 3 months of compression
stockings. EVA candidates were treated with laser ablation or radiofrequency
ablation using a standardized technique. All patients who were identified as
potential high risk for DVT had hematology consultation and were pre-
scribed periprocedural anticoagulation prophylactically. Postprocedural ul-
trasonography was performed at 1 week, 1 month, 3 months, and every 6
months thereafter for 2 years.
Results: A total of 685 EVA were performed (480 laser, 205 radiofre-
quency), most in the great saphenous veins. A subgroup of 15 patients
(2.1%) was identified to be high risk for DVT.Mean age was 44 years. CEAP
classifications ranged from 2 to 6, with ankle edema being themost common
diagnosis. The immediate technical success rate was 99.6%. Access failure
occurred in three patients (0.4%). The most common postprocedural com-
plications included bruising in 203 (29%), phlebitis in branch varicosities in
28 (4%), and heat induced thrombus formation in 13 (1.9%). There was no
significant difference between laser and radiofrequency groups. None of the
presumed hypercongealable patients developed thrombotic complications.
There were no deaths in this series. Mean follow-up was 6 months (range,
1-27 months). Ancillary procedures were performed in 19%, including stab
phlebectomy, sclerotherapy, and perforator injection or ablations. All pa-
tients remain successfully ablated to date.
Conclusions: In our experience, EVA can be safely performed in
appropriate candidates with excellent clinical outcomes and minimal mor-
bidity and mortality. Preliminary data suggests that patients with hyperco-
agulable conditions or strong family history of thrombosis can be considered
for EVA with periprocedural anticoagulation.
Clinical Outcomes With Covered Stent Placement for Central Venous
Occlusive Disease in Hemodialysis Patients
Javier E. Anaya-Ayala, MD, Cherie Obilom, BS, Zulfiqar F. Cheema, MD,
PhD, Joseph J. Naoum, MD, Jean Bismuth, MD, Mark G. Davies, MD,
PhD, Alan B. Lumsden, MD, and Eric K. Peden, MD, Methodist DeBakey
Heart and Vascular Center, Houston, Tex
Objectives:The use of covered stents (CSs) has been proposed as a new
treatment option for central venous occlusive disease (CVOD) in hemodi-
alysis patients. Among its advantages include the mechanical support of
bare-metal stents while providing an inert and stable intravascular matrix for
endothelialization. The aim of this study is to evaluate the efficacy and
durability of CSs in treating central venous stenosis while preserving hemo-
dialysis access patency.
Methods: A retrospective review was performed in all patients with
symptomatic CVOD manifested with venous hypertension or access mal-
function and treated by means of CS from April 2007 to March 2010. The
Gore Viabahn Endoprosthesis stent graft was implanted in all cases. Patients’
demographics, stenotic lesions location, stent graft, and patency were deter-
mined; complications, reintervention, and factors influencing their out-
comes were examined.
Results: Twenty patients (60% men) with a mean age of 56 years
(range, 28 to 86) primarily underwent CS placement for CVOD. Of the 20,
18 (90%) had history of arterial hypertension, 13 (65%) were diabetic, and 4
(20%) had peripheral arterial disease. All patients had a history of multiple
central catheter placements. The indications for the CS placement were
access malfunction with angioplasty-resistant lesions in 12 patients (60%)
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nical success and resolution of the symptoms was achieved in all cases.
Locations CS placements are summarized in the Table. The mean
follow-up was 8.4 months, 3 cases (15%) of thrombosis occurred within
the first 3 months of stent placement requiring percutaneous thrombec-
tomy and percutaneous transluminal angioplasty (PTA). Three patients
required PTA for restenosis. The overall primary patency, assisted pri-
mary patency, and secondary patency were 66%, 94%, and 100% at 12
months, respectively.
Conclusion: Endovascular therapy with CS for CVOD is safe and
effective in hemodialysis patients. In the present series, we demonstrated
promising results with higher primary and secondary patency than angio-
plasty and bare-metal stents. CS placement should be considered in recalci-
trant lesions; however, further prospective and randomized studies are
necessary to determine whether CSs provide superior long-term results to
those achieved with PTA and bare-metal stents.
Location of covered stent placements
Location Subclavian vein Innominate vein Both veins
Right 1 5 5
Left 4 5 0
Placement Issues forHemodialysis CathetersWith Pre-existing Central
Lines and Catheters
Anil Hingorani, Daniel Jung, DO, Jerry Walkup, MS, Enrico Ascher, MD,
Natalie Marks, MD RVT, Alexsander Shiferson, DO, Kapil Gopal, MD, and
Theresa Jacob, PhD, Maimononides Medical Center, Brooklyn, NY
Background: It has been a widely accepted practice that a previously
placed pacemaker was a contraindication to placing a hemodialysis catheter
in the ipsilateral internal jugular vein. Fear of dislodging pacing wires,
tunneling close to the battery site, or causing venous obstruction has been a
concern for surgeons and interventionalists alike. We suggest that this
phobia is unfounded.
Methods: This is a retrospective review of 600 hemodialysis catheters
placed between 1999 and 2009. For each hemodialysis catheter that was
placed, the perioperative chest x-ray image was examined to evaluate for
pre-existing pacemakers and central catheters.
Results:We found 20 pacemakers and 19 central catheters on the same
side of the neck as the hemodialysis catheter that was placed in the ipsilateral
jugular vein. Subclavian central catheters were also left in place for these
procedures. The mean age of the patients was 73.6  12 years (median, 76
years). No patient exhibited malfunction or dislodgment of the central
catheter, the pacemaker, or automated implantable cardioverter-defibrillator
(AICD), or evidence of upper extremity venous obstruction based on signs
symptoms or duplex examinations.
Conclusions: Since the updated Disease Outcomes Quality Initia-
tive (DOQI) guidelines call for placement of the arteriovenous fistula
opposite the side of the hemodialysis catheter, pacemakers and AICDs,
we suggest the policy of placing the hemodialysis catheter in the ipsilat-
eral internal jugular vein is safe and spares the contralateral limb for
arteriovenous fistula creation.
Scientific Session II
Cervical Ribs—A Rare Entity but Clinically Significant
Julie A. Freischlag, MD, Kevin Chang, BS, Merve Gurkar, Thomas Reifsnyder,
MD, and Kylie Davis, Johns Hopkins Medical Institutions, Baltimore, Md
Objectives: Owing to their unique presentation, we reviewed our
operative experience in patients with large, clinically significant cervical ribs.
Methods: This was a retrospective review of a prospectively acquired
database.
Results: Between January 2006-December 2009, 19 patients (16
women)with cervical ribs underwent first rib resection and cervical rib resection.
Patients were an average age of 35 years (range, 16-51 years). Fourteen patients
had sustained arterial compromise as a result of their cervical ribs. Six patients
presented with arterial thrombosis, and two also had a venous thrombosis at
presentation. Five patients had undergone thrombolysis, one had received
angioplasty, and thrombectomy procedures had been attempted in two. Three
patients had visible and palpable pulsatile masses: one was painful, and one had
embolized. One patient had had a previous partial cervical rib resection. Three
patients underwent contralateral prophylactic operations due to the presence of
a cervical rib. The remaining five patients had neurogenic symptoms as the
indication for their operation. A transaxillary approach was used in 20 of the 22
operations to remove both the first rib and the cervical rib. The cervical rib was
fused to the first rib in 17 of 22 cases (77%).) A supraclavicular approach wasused in two patients to resect the axillosubclavian aneurysm and place an
interposition graft. All patients did well but required postoperative physical
therapy to gain strength and range of motion.
Conclusions: Significant cervical ribs are large and frequently are
fused to the first rib, which results in arterial compression or aneurysm
formation. Thrombosis and embolization can occur and causes arterial
ischemia. In these patients, both the cervical rib and the first rib must be
removed to relieve the arterial compromise and can be done safely
through a transaxillary approach. Only those patients with aneurysms
who need to have the artery resected and replaced should undergo a
supraclavicular approach.
Scientific Session III
Clinical Outcomes for Hostile Versus Favorable Aortic Neck Anatomy
in Endovascular Aortic Aneurysm Repair Using Modular Devices
Ali F. AbuRahma, MD, John E. Campbell, MD, Albeir Y. Mousa, MD,
Akhilesh Jain, MD, Patrick A. Stone, MD, Stephen M. Hass, MD, Aravinda
Nanjundappa, MD, L Scott Dean, MD, and Tammi Keiffer, RN, Robert C.
Byrd Health Sciences Center of W. Va. University, Charleston, WVa
Objective: This study analyzed the clinical implications of various
clinical features of proximal aortic neck anatomy in EVAR using modular
devices.
Methods: A total of 258 EVAR patients were divided into favorable
(FNA) or hostile neck anatomy (HNA). HNA was defined as having one or
more of the following features: length of10 mm, angle of60°, diameter of
28 mm, 50% circumferential thrombus, 50% calcified neck, and reverse
taper.
Results: Thirty-seven percent of patients had FNA and 63% had HNA.
TheHNA group included 46 angulated, 20 short, 19 dilated (28mm), 16
calcified, 93 thrombus lined, and 51 reverse tapered. The technical success
was 99%. The mean follow-up was 22 months (range, 1-78 months). The
perioperative complication and death rates for FNA were 3% and 0% vs 16%
and 3% for HNA (P  .0027). Operative blood loss, contrast volume, and
operative time were similar for both groups. Proximal type I early endoleaks
occurred in 9% of FNA vs 23% for HNA (P  .0068). Intraoperative
proximal aortic cuffs were used to seal endoleaks in 8% for FNA vs 22% for
HNA (P .0044). AAA expansion was noted in 6% for FNA vs 7% for HNA
(P  .8509). Rates of freedom from late type I endoleaks at 1, 2, 3, and 4
years were 97%, 97%, 97%, and 90% for FNA vs 89%, 89%, 89%, and 89% for
HNA (P  .1224; Fig 1). Graft patency rates at 1, 2, and 3 years were 99%,
99%, and 99% for FNA vs 97%, 92%, and 90% for HNA (P  .0925; Fig 2).
The rates for late interventions were 95%, 90%, 90%, and 90% for FNA vs
95%, 93%, 91%, and 85% for HNA (P  .6902; Fig. 3). The survival rates
were 93%, 84%, 76%, and 76% for FNA vs 88%, 82%, 74%, and 66% for HNA
(P  .2631; Fig. 4). Multivariate logistic regression analysis revealed that
reverse taper was a significant predictor for early type I endoleak (OR, 5.25,
P  .0001), reverse taper (OR, 5.95, P  .0001), and neck length (OR,
4.15, P  .0146) were predictors for aortic cuff use and circumferential
thrombus (OR, 2.44, P .0448) and neck angle (OR, 3.38, P .009) were
predictors for perioperative complications.
Conclusions: Patients with HNA can be treated with EVAR, but with
higher rates of early type I endoleak and intervention. However, the mid-
term outcomes were similar to FNA.
